PDCD1 and neoplasm: As shown in Figure S2A–C, the anti-PD-1 antibody combined with cabozantinib plus celecoxib or chidamide-k30 regimen achieved excellent tumor growth inhibition when compared with the anti-PD-1 antibody treatment alone.